{
    "2019-12-04": [
        [
            {
                "time": "2023-02-05",
                "original_text": "涨停板早知道：七大利好有望发酵",
                "features": {
                    "keywords": [
                        "涨停板",
                        "利好",
                        "发酵"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "综合"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            },
            {
                "time": "2023-02-05",
                "original_text": "贝达药业：BPI-27336药品临床试验申请受理 拟用于实体瘤治疗",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-27336",
                        "临床试验",
                        "实体瘤",
                        "受理"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-02-05",
                "original_text": "贝达药业：创新药BPI-27336药品临床试验申请获得受理",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-27336",
                        "创新药",
                        "临床试验",
                        "受理"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-02-05",
                "original_text": "贝达药业：申报的BPI-27336片的药品临床试验申请已经获得国家药品监督管理局受理",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-27336",
                        "药品",
                        "临床试验",
                        "受理",
                        "国家药品监督管理局"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}